Abstract
Abstract Personalized neoantigen therapies for cancer require accurate epitope selection. However, most Class I prediction algorithms in common use today are based on biochemical binding assays that are difficult to scale and do not address processing steps upstream of peptide-MHC binding. Here we present an alternative approach based on the LC-MS/MS identification of MHC Class I-bound peptides. While MS-based profiling is not new, we optimized the system for rule learning by focusing on cell lines expressing only a single HLA-A or HLA-B allele and by collecting parallel transcriptomic and proteomic measurements. Identifying over 24,000 peptides across 16 individual alleles, we were able to discover novel binding motifs, which were validated biochemically, and develop novel neural network algorithms. Furthermore, we systematically interrogated processing rules - discovering a novel motif conserved across multiple cell types - and developed a principled framework for integrating epitope cleavability, expression, and MHC binding potential into an overall ranking. Validating on external datasets, we saw a doubling in positive predictive value with respect to standard approaches. We thus demonstrate a scalable strategy for systematically learning the rules of endogenous antigen presentation that can be deployed for the optimal selection of patient-specific cancer neoantigens. Citation Format: Michael S. Rooney, Jenn Abelin, Siranush Sarkizova, Derin Keskin, Christine Hartigan, Wandi Zhang, John Sidney, William Lane, Jonathan Stevens, Guang L. Zhang, Karl Clauser, Nir Hacohen, Steve Carr, Cathy Wu. Next-generation epitope prediction using mass spectrometry and integrative genomics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr LB-179. doi:10.1158/1538-7445.AM2017-LB-179
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.